hotspot -WSS

hotspot

author：entertainment 2025-09-27 19:37:36 - browse：562

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Verily hires former Apple Health leader as chief scientific officer

WSS

Robert Kennedy Jr.'s presidential campaign attracts GOP

A look at other Americans who have crossed into North Korea over the years

White House drug shortage group privately met with industry

Gilgo Beach: Police identify another victim in serial killing investigation

Manchin plays down potential 3rd

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

focus

hotspot

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

Nearly two

Peter Hotez and the public health issue of online harassment

Manchin plays down potential 3rd

In age of alternative facts, a scholarly course on calling out crap

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Supreme Court strikes down use of affirmative action

More hospitals are billing patients as online messages surge

23andMe had bad news about my health. I wish a person had delivered it

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

hotspot

Stem cell clinics for heart failure: buyer be wary

For BCIs, commercial hurdles may be bigger than scientific ones

A look at other Americans who have crossed into North Korea over the years

OTC birth control: A brief history of over the counter pill design

What Mike Pence has said that could be used in a Donald Trump trial

White House drug shortage group privately met with industry

focus

hotspot

entertainment

focus